Upadacitinib versus tofacitinib in anti-MDA5-positive dermatomyositis with interstitial lung disease: a multi-center cohort study emulating a target trial

Published: 13 October 2025| Version 1 | DOI: 10.17632/tryrj36zpm.1
Contributor:
Can Xia

Description

Supplementary material for the study “Upadacitinib versus tofacitinib in anti-MDA5-positive dermatomyositis with interstitial lung disease: a multi-center cohort study emulating a target trial.”

Files

Institutions

  • Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital
  • Wenzhou Medical University First Affiliated Hospital
  • Guangzhou Medical College First Affiliated Hospital
  • Huashan Hospital Fudan University
  • Zhejiang University School of Medicine Second Affiliated Hospital

Categories

Rheumatology, Treatment of Interstitial Lung Disease, Dermatomyositis, Interferon Type I, Janus Kinase

Related Links

Dataset
https://data.mendeley.com/datasets/tryrj36zpm/1
is related to this dataset

Licence